NANX NANOPHASE TECHNOLOGIES
Nanophase Technologies Corp. engages in the development and provision of engineered nanomaterial solutions. Its products include metal oxides with aluminum, antimony tin, bismuth, cerium, iron, and zinc. The firm's product is used in variety of markets including surface finishing, exterior coatings, personal care, plastics, scratch resistant coatings, and textiles. The company was founded by Richard W. Siegel on November 25, 1989 and is headquartered in Romeoville, IL.
Company profile
Ticker
NANX
Exchange
Website
CEO
Jess A. Jankowski
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
DMC Global • Steel Partners ...
Former names
NANOPHASE TECHNOLOGIES CORPORATION
SEC CIK
Corporate docs
IRS number
363687863
NANX stock data
()
Investment data
Securities sold
Number of investors
Calendar
17 May 21
24 Jun 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.82M | 1.82M | 1.82M | 1.82M | 1.82M | 1.82M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) | 45.67K | 84.83K |
| Cash used (since last report) | n/a | n/a | n/a | n/a | 127.25K | 236.4K |
| Cash remaining | n/a | n/a | n/a | n/a | 1.69M | 1.58M |
| Runway (months of cash) | n/a | n/a | n/a | n/a | 37.0 | 18.7 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 May 21 | Whitmore Bradford T | Common Stock | Conversion | Aquire C | No | No | 0.2 | 10,095,555 | 2.02M | 29,625,290 |
| 7 May 21 | Whitmore Bradford T | 2% Second Secured Convertible Note Common Stock | Conversion | Dispose C | No | No | 0.2 | 2,019,111 | 403.82K | 0 |
| 23 Dec 20 | Whitmore R Janet | Common Stock | Buy | Aquire P | No | No | 0.75 | 50,000 | 37.5K | 1,467,055 |
| 8 Dec 20 | Whitmore R Janet | Common Stock | Buy | Aquire P | No | No | 0.76 | 19,100 | 14.52K | 1,417,055 |
| 30 Nov 20 | Whitmore R Janet | Common Stock | Buy | Aquire P | No | No | 0.68 | 700 | 476 | 1,397,955 |
| 28 Oct 20 | Laura M Beres | Common Stock Common Stock | Grant | Aquire A | No | No | 0.62 | 10,000 | 6.2K | 10,000 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
1.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 601.41K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Whitmore Bradford T | 601.41K | $0 |
Financial report summary
?Management Discussion
- Total revenue increased to $7,072,000 for the three months ended March 31, 2021, compared to $4,039,000 for the same period in 2020.
- A substantial majority of our revenue for both periods was from our five largest customers, in particular, sales to our largest customer in skin care and sunscreen applications, medical diagnostics, and now finished skin health products marketed through our Solésence subsidiary. Product revenue, the primary component of our total revenue, increased to $7,050,000 three months ended March 31, 2021, compared to $3,961,000 during the same period of 2020. This increase was due to continued growth in the adoption of our Solésence® products and our medical diagnostics materials, offset by a decrease in revenue from our largest customer in our personal care ingredients business.
- Other revenue decreased to $22,000 for the three months ended March 31, 2021, compared to $78,000 for the three months ended March 31, 2020. Other revenue is typically comprised primarily of developmental or licensing fees. For the three months ended March 31, 2020, other revenue included $65,000 to development fees recognized for the Company’s work on behalf of a customer relating to new personal care ingredients.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Good
|
|
New words:
appetite, biggest, burst, Chain, chose, confluence, constrained, core, cosmetic, curb, cyclicality, deep, deliver, enable, enabled, enhance, enhanced, enhancing, February, fight, floor, grown, handling, ingredient, innovation, instance, IRC, issue, knowledge, legacy, Leveraging, markedly, maximize, met, multiple, packaging, PCR, Pharmaceutical, platform, play, Polymerase, postponed, predict, professional, proven, rapidly, recognition, reoriented, request, requesting, science, serve, shown, slightly, storage, unexpected, unprecedented, viral, wellbeing
Removed:
Accounting, achieve, achievement, Aid, approve, arise, assuming, authorization, aware, began, belief, Board, calculate, carry, case, cease, chemical, classified, clear, coated, Codification, commencement, commitment, consulting, consumer, contingent, continuation, contractual, corporate, declared, deferred, designated, determine, Division, duration, earned, enter, essential, estimate, expiration, extended, fee, fluid, fulfill, global, Governor, healthcare, inaccurate, indefinitely, infrastructure, initial, input, investor, JDA, Joint, jointly, law, low, manage, model, nanocrystalline, national, negative, ongoing, Organization, OTC, outbreak, outlook, pandemic, presentation, proportionally, qualify, quantifiable, realized, recent, recognizing, reduction, refunded, Relief, remuneration, return, SCOA, skincare, state, subsequently, Sumitomo, table, taxable, Title, transaction, unknowable, visibility, vital, world, worldwide
Financial reports
10-Q
2021 Q1
Quarterly report
17 May 21
10-K
2020 FY
Annual report
26 Mar 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
12 Aug 20
10-Q
2020 Q1
Quarterly report
13 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
4 Apr 19
Current reports
8-K
Entry into a Material Definitive Agreement
14 Jun 21
8-K
Nanophase Reports Record First Quarter Financial Results as Solésence Beauty Science Leads Growth
27 Apr 21
8-K
Entry into a Material Definitive Agreement
21 Apr 21
8-K
Nanophase Reports Record 2020 Financial Results as Solésence Beauty Science and Life Science Materials Lead Growth
11 Mar 21
8-K
Entry into a Material Definitive Agreement
23 Dec 20
8-K/A
Departure of Directors or Certain Officers
4 Nov 20
8-K
Nanophase Reports Record Third Quarter 2020 Financial Results as Solésence Expands Beauty Footprint
3 Nov 20
8-K
Laura M. Beres Joins Nanophase Board of Directors as Solésence Expands Beauty Footprint
30 Oct 20
8-K
Entry into a Material Definitive Agreement
21 Sep 20
8-K
Entry into a Material Definitive Agreement
2 Sep 20
Registration and prospectus
S-8
Registration of securities for employees
20 Apr 21
D
$1M in equity, sold $1M, 1 investor
20 Dec 17
D
$988K in equity, sold $988K, 1 investor
10 Feb 16
S-8
Registration of securities for employees
31 Mar 13
424B3
Prospectus supplement
13 Jun 12
S-1/A
IPO registration (amended)
7 Jun 12
S-1
IPO registration
16 May 12
25
Voluntary exchange delisting
19 Mar 12
S-3/A
Shelf registration (amended)
21 Jan 10
S-3
Shelf registration
24 Nov 09
Proxies
DEF 14A
Definitive proxy
13 Nov 20
DEFA14A
Additional proxy soliciting materials
14 Nov 19
DEF 14A
Definitive proxy
17 Oct 19
PRE 14A
Preliminary proxy
7 Oct 19
DEFA14A
Additional proxy soliciting materials
13 Jul 18
DEF 14A
Definitive proxy
13 Jul 18
DEF 14A
Definitive proxy
13 Jul 17
DEFA14A
Additional proxy soliciting materials
13 Jul 17
DEF 14A
Definitive proxy
14 Jul 16
DEFA14A
Additional proxy soliciting materials
14 Jul 16
Other
CT ORDER
Confidential treatment order
9 May 19
CT ORDER
Confidential treatment order
19 Jun 18
SD
Conflict minerals disclosure
31 May 18
CT ORDER
Confidential treatment order
24 Jul 17
SD
Conflict minerals disclosure
29 May 17
CT ORDER
Confidential treatment order
20 Dec 16
CT ORDER
Confidential treatment order
10 Jul 16
SD
Conflict minerals disclosure
30 May 16
CT ORDER
Confidential treatment order
2 Feb 15
CT ORDER
Confidential treatment order
10 Feb 13
Ownership
4
NANOPHASE TECHNOLOGIES / BRADFORD T WHITMORE ownership change
11 May 21
SC 13G/A
NANOPHASE TECHNOLOGIES / Conley John Howard Jr ownership change
1 Feb 21
4
NANOPHASE TECHNOLOGIES / R JANET WHITMORE ownership change
28 Dec 20
4
NANOPHASE TECHNOLOGIES / R JANET WHITMORE ownership change
10 Dec 20
4
NANOPHASE TECHNOLOGIES / R JANET WHITMORE ownership change
2 Dec 20
SC 13D/A
NANOPHASE TECHNOLOGIES / WHITMORE BRADFORD T ownership change
6 Nov 20
4
NANOPHASE TECHNOLOGIES / Laura M Beres ownership change
30 Oct 20
SC 13D/A
NANOPHASE TECHNOLOGIES / WHITMORE BRADFORD T ownership change
1 Oct 20
4
NANOPHASE TECHNOLOGIES / BRADFORD T WHITMORE ownership change
1 Oct 20
4
NANOPHASE TECHNOLOGIES / R JANET WHITMORE ownership change
14 Sep 20
Patents
APP
Utility
Lipophillically Dispersed Phenolic Polymer Particles
18 Mar 21
A composition comprises phenolic polymer particles and a surfactant, on the phenolic polymer particles.
APP
Utility
Method of Enhancing the Efficacy and Stability of Ingredients In Suspensions
11 Feb 21
A composition comprises a low-solubility ingredient having a particle size of at most 10 μm dispersed in a solvent.
APP
Utility
Coated Powders Having High Photostability
17 Jun 20
A coated powder comprises (a) particles, and (b) a coating on the surface of the particles including (1) silica moieties, (2) organo oxysilane moieties selected from the group consisting of mono-organo oxysilane moieties, bi-organo oxysilane moieties and tri-organo oxysilane moieties, and (3) poly(dialkyl)siloxane moieties.
APP
Utility
Multifunctional Coated Powders and High Solids Dispersions
20 May 20
A coated powder comprises (a) nanoparticles, and (b) a coating, on the surface of the nanoparticles.
GRANT
Utility
Coated powders having high photostability
16 Mar 20
A coated powder comprises (a) particles, and (b) a coating on the surface of the particles including (1) silica moieties, (2) organo oxysilane moieties selected from the group consisting of mono-organo oxysilane moieties, bi-organo oxysilane moieties and tri-organo oxysilane moieties, and (3) poly(dialkyl)siloxane moieties.